Nebiloc (Nebivolol)

• Nebivolol is indicated for conditions within the cardiovascular disease pathway, primarily to control blood pressure and support cardiac function.
• Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk.
• Heart failure: improves left‑ventricular ejection fraction and reduces symptoms of chronic heart failure.
• High cardiovascular risk: may be used as part of a risk‑reduction strategy when indicated by a physician.

• Nebivolol selectively blocks β1‑adrenergic receptors, decreasing heart rate and myocardial contractility, which reduces cardiac output and blood pressure. In addition, it stimulates endothelial nitric oxide synthase, enhancing nitric oxide release and causing vasodilation, further contributing to its antihypertensive effect.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or light‑headedness, especially on standing.
• Fatigue or tiredness.
• Nasal congestion or rhinorrhea.
• Nausea or mild gastrointestinal upset.
• Bradycardia: heart rate slower than normal.

Serious or Rare Side Effects

• Severe bradycardia or heart block.
• Marked hypotension leading to fainting.
• Bronchospasm in patients with asthma or COPD.
• Allergic reactions such as rash, pruritus, or angio‑edema.
• Hepatic dysfunction or elevated liver enzymes.
• Acute heart failure decompensation.

• Nebivolol requires careful monitoring and patient education before and during therapy.
• Monitor blood pressure: ensure target levels are achieved without excessive drop.
• Assess heart rate: watch for bradycardia, especially in patients with conduction disorders.
• Use caution in asthma/COPD: β1‑selectivity reduces but does not eliminate risk of bronchospasm.
• Avoid abrupt discontinuation: taper dose to prevent rebound hypertension.
• Adjust dose in renal impairment: consider reduced dosing in severe renal dysfunction.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid)

• Other β‑blockers: additive bradycardia and hypotension.
• Calcium channel blockers (verapamil, diltiazem): increased risk of AV block.
• Potent CYP2D6 inhibitors (paroxetine, fluoxetine): raise nebivolol plasma levels.
• Combined antihypertensives (e.g., ACE inhibitors, ARBs) in high doses: may cause severe hypotension.

Moderate Interactions (Monitor Closely)

• Diuretics: monitor electrolytes and blood pressure.
• Digoxin: watch for bradyarrhythmias.
• NSAIDs: may blunt antihypertensive effect.
• Clonidine: risk of rebound hypertension if stopped abruptly.
• Antidiabetic agents: monitor glucose as β‑blockade can mask hypoglycemia symptoms.